Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PharmPAP: Inhaled Sargramostim in Autoimmune PAP
NCT03006146Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jul 2017
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Occurrence of any treatment-emergent adverse events and serious adverse events at 1 year. Started Jul 2017; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT03006146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006146.